• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Bioceres Crop Solutions Corp.

    6/10/25 5:57:54 PM ET
    $BIOX
    Agricultural Chemicals
    Industrials
    Get the next $BIOX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 13)


    Bioceres Crop Solutions Corp.

    (Name of Issuer)


    Ordinary Shares, $0.0001 par value

    (Title of Class of Securities)


    G1117K114

    (CUSIP Number)


    Gloria Montaron Estrada
    Bioceres Group Limited, Highdown House, Yeoman Way, Worthing,
    West Sussex, X0, BN99 3HH
    54 0341 4861100


    Matthew S. Poulter
    1290 Avenue of the Americas,
    New York, NY, 10104
    12129039000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    06/06/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    G1117K114


    1 Name of reporting person

    Bioceres Group Limited
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    70,785.00
    8Shared Voting Power

    25,044,317.00
    9Sole Dispositive Power

    70,785.00
    10Shared Dispositive Power

    21,968,238.00
    11Aggregate amount beneficially owned by each reporting person

    25,115,102.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    40.0 %
    14Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:
    Bioceres Group Limited may be deemed to be the ultimate beneficial owner of Shares held by Bioceres LLC and THEO I SCSp as Bioceres LLC is an indirect wholly-owned subsidiary of Bioceres Group Limited, and Bioceres Group Limited owns 96.2 percent of the outstanding equity securities of THEO I SCSp. Row 8 includes 3,076,079 shares that Bioceres LLC has shareholder rights over pursuant to the Shareholders Agreement, dated as of March 5, 2019, by and between Bioceres LLC, Pedro Enrique Mac Mullen, Maria Marta Mac Mullen and International Property Services Corp. See Exhibit 10.1.


    SCHEDULE 13D

    CUSIP No.
    G1117K114


    1 Name of reporting person

    Bioceres LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    21,544,317.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    18,468,238.00
    11Aggregate amount beneficially owned by each reporting person

    21,544,317.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    34.3 %
    14Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:
    Bioceres LLC is an indirect wholly-owned subsidiary of Bioceres Group Limited. As a result, Bioceres Group Limited may be deemed to be the ultimate beneficial owner of Shares held by Bioceres LLC Row 8 includes 3,076,079 shares that Bioceres LLC has shareholder rights over pursuant to the Shareholders Agreement, dated as of March 5, 2019, by and between Bioceres LLC, Pedro Enrique Mac Mullen, Maria Marta Mac Mullen and International Property Services Corp. See Exhibit 10.1.


    SCHEDULE 13D

    CUSIP No.
    G1117K114


    1 Name of reporting person

    THEO I SCSp
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    LUXEMBOURG
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,500,000.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,500,000.00
    11Aggregate amount beneficially owned by each reporting person

    3,500,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.6 %
    14Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:
    Bioceres Group Limited owns 96.2 percent of the outstanding equity securities of THEO I SCSp. As a result, Bioceres Group Limited may be deemed to be the ultimate beneficial owner of Shares held by THEO I SCSp.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, $0.0001 par value
    (b)Name of Issuer:

    Bioceres Crop Solutions Corp.
    (c)Address of Issuer's Principal Executive Offices:

    Ocampo 210 bis, Predio CCT, Rosario, Province of Santa Fe, ARGENTINA , 2000.
    Item 1 Comment:
    EXPLANATORY NOTE - This Amendment No. 13 (the "Amendment") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 14, 2019, (as amended by Amendment No. 1 filed with the SEC on July 2, 2020, Amendment No. 2 filed with the SEC on August 28, 2020, Amendment No. 3 filed with the SEC on November 25, 2020, Amendment No. 4 filed with the SEC on August 6, 2021, Amendment No. 5 filed with the SEC on October 15, 2021, Amendment No. 6 filed with the SEC on April 5, 2022, Amendment No. 7 filed with the SEC on July 25, 2022, Amendment No. 8 filed with the SEC on November 15, 2022, Amendment No. 9 filed with the SEC on March 25, 2024, Amendment No. 10 filed with the SEC on September 20, 2024, Amendment No. 11 filed with the SEC on January 6, 2025 and Amendment No. 12 filed with the SEC on March 28, 2025 (the "Schedule 13D"), by Bioceres Group Limited, Bioceres LLC and Theo I SCSp (each a "Reporting Person", and herein collectively referred as the "Reporting Persons").
    Item 2.Identity and Background
    (a)
    Bioceres Group Limited, which is the holder of record of 70,785 Shares (corresponding to approximately 0.1% of the Issuer's outstanding capital stock) and through its subsidiaries Bioceres LLC and Theo I SCSp, holds an additional 21,968,238 Shares (corresponding to approximately 35.0% of the Issuer's outstanding capital stock); Bioceres LLC, which is the holder of record of 18,468,238 Shares (corresponding to approximately 29.4% of the Issuer's outstanding capital stock); and THEO I SCSp, which is the holder of record of 3,500,000 Shares (corresponding to approximately 5.6% of the Issuer's outstanding capital stock). Bioceres Group Limited is Highdown House, Yeoman Way, Worthing, West Sussex, United Kingdom, BN99 3HH;
    (b)
    Bioceres LLC is 1209 Orange Street, Wilmington 19801-1120, County of New Castle; and THEO I SCSp is 30 boulevard Royal, L-2449 Luxembourg.
    (c)
    Not applicable.
    (d)
    None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    None of the Reporting Persons has, during the last five years, been a party to civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Bioceres Group Limited is a company organized under the laws of England and Wales; Bioceres LLC is limited liability company formed under the laws of Delaware; and THEO I SCSp is a special limited partnership (societe en commandite speciale) incorporated in the Grand Duchy of Luxembourg.
    Item 3.Source and Amount of Funds or Other Consideration
     
    This Amendment is being filed to report a decrease in the Shares beneficially owned by the Reporting Persons, as a result of the settlement of certain financial obligations of the Reporting Persons through payment-in-kind made in Shares relating to a private transaction (the "Transaction"). As a result of the foregoing, the Shares owned by the Reporting Persons decreased from 24,611,039 to 22,039,023. The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as expressly amended and supplemented by this Amendment, the Schedule 13D is not amended or supplemented in any respect. Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Schedule 13D. The aggregate percentages of Shares beneficially owned by the Reporting Persons, and reported in this Amendment, is calculated based on 62,848,483 Shares outstanding, as reported by the Issuer in its annual report on Form 20-F filed with the SEC on October 30, 2024 (File No. 001-38836) (the "Issuer 20-F").
    Item 4.Purpose of Transaction
     
    The purpose of the Transaction was to fund the payment of financial obligations which were due. As a result of the Transaction, the Shares owned by the Reporting Persons, which are not subject to the shareholders' agreement described under Item 6 of the Schedule 13D, decreased from 24,611,039 Shares to 22,039,023 Shares. In addition, 3,076,079 Shares which the Reporting Persons have the shared power to vote or to direct the vote of are subject to the shareholders' agreement described under Item 6 of the Schedule 13D. As a result of the foregoing, in the aggregate, the Reporting Persons beneficially own 25,115,102 Shares (corresponding to approximately 40.0% of the Issuer's outstanding capital stock). Except for the foregoing, the Reporting Persons have no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    Bioceres Group Limited: Amount beneficially owned: 25,115,102 - Percentage: 40.0% Bioceres LLC: Amount beneficially owned: 18,468,238 - Percentage: 29.4% THEO I SCSp: Amount beneficially owned: 3,500,000 - Percentage: 5.6%
    (b)
    Bioceres Group Limited: Sole power to vote or to direct the vote: 70,785 Shared power to vote or to direct the vote: 25,044,317 Sole power to dispose or to direct the disposition of: 70,785 Shared power to dispose or to direct the disposition of: 21,040,254 Bioceres LLC: Sole power to vote or to direct the vote: -- Shared power to vote or to direct the vote: 21,544,317 Sole power to dispose or to direct the disposition of: -- Shared power to dispose or to direct the disposition of: 18,468,238 THEO I SCSp Sole power to vote or to direct the vote: -- Shared power to vote or to direct the vote: 3,500,000 Sole power to dispose or to direct the disposition of: -- Shared power to dispose or to direct the disposition of: 3,500,000
    (c)
    None of the Reporting Persons has effected any transactions of the Issuer's Shares during the 60 days preceding the date of this report, except as described in Item 4 of this Schedule 13D/A which information is incorporated herein by reference.
    (d)
    Not applicable.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Not applicable.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 10.1* Shareholders Agreement, dated as of March 5, 2019, by and among Bioceres LLC, Pedro Enrique Mac Mullen, Maria Marta Mac Mullen and International Property Services Corp. Exhibit 99.1* Joint Filing Agreement dated March 25, 2024, by and among the Reporting Persons. * Previously filed.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Bioceres Group Limited
     
    Signature:/s/ Gloria Montaron Estrada
    Name/Title:Gloria Montaron Estrada/ Attorney-in-Fact
    Date:06/10/2025
     
    Bioceres LLC
     
    Signature:/s/ Gloria Montaron Estrada
    Name/Title:Gloria Montaron Estrada/ Manager
    Date:06/10/2025
     
    THEO I SCSp
     
    Signature:/s/ Gloria Montaron Estrada
    Name/Title:Gloria Montaron Estrada/ Attorney-in-Fact
    Date:06/10/2025
    Get the next $BIOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOX

    DatePrice TargetRatingAnalyst
    7/19/2024$17.00Buy
    Canaccord Genuity
    7/2/2024$15.00Buy
    ROTH MKM
    4/6/2023$15.00Outperform
    Oppenheimer
    9/30/2022$22.50Buy
    Canaccord Genuity
    10/8/2021$21.00Buy
    ROTH Capital
    More analyst ratings

    $BIOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bioceres Crop Solutions Reports Fiscal Third Quarter 2025 Financial and Operational Results

      Total revenues in 3Q25 were $60.6 million 3Q25 net loss was $1.6 million and Adjusted EBITDA1 was $9.0 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal third quarter ended March 31, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Total revenues were $60

      5/21/25 7:01:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions to Host Fiscal Third Quarter 2025 Financial Results Conference Call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time

      Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time to discuss its results for the fiscal third quarter ended March 31, 2025. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube, Chief Commercial Officer Milen Marinov and Head of Investor Relations Paula Savanti will host the conference ca

      5/9/25 4:30:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions Announces EPA Registration of Rinotec Insecticide and Nematicide Platform, a Game-Changing Solution for Integrated Pest Management

      Bioceres Crop Solutions (NASDAQ:BIOX), a leading global provider of sustainable crop productivity solutions, and ProFarm Group, a subsidiary of BIOX, today announced that their innovative insecticide and nematicide platform, Rinotec, has received a federal registration from the U.S. Environmental Protection Agency (EPA). Rinotec is exempt from residue tolerance requirements, reflecting the EPA's assessment of its negligible risk to human health and non-target organisms. Rinotec has already been approved for commercialization in Brazil. With both U.S. and Brazilian registrations now in place, Bioceres Crop Solutions is poised to advance its regulatory and commercial strategies in these regi

      3/11/25 7:30:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity resumed coverage on Bioceres with a new price target

      Canaccord Genuity resumed coverage of Bioceres with a rating of Buy and set a new price target of $17.00

      7/19/24 8:32:10 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • ROTH MKM resumed coverage on Bioceres with a new price target

      ROTH MKM resumed coverage of Bioceres with a rating of Buy and set a new price target of $15.00

      7/2/24 8:01:46 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Oppenheimer initiated coverage on Bioceres with a new price target

      Oppenheimer initiated coverage of Bioceres with a rating of Outperform and set a new price target of $15.00

      4/6/23 7:19:53 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Financials

    Live finance-specific insights

    See more
    • Bioceres Crop Solutions Reports Fiscal Third Quarter 2025 Financial and Operational Results

      Total revenues in 3Q25 were $60.6 million 3Q25 net loss was $1.6 million and Adjusted EBITDA1 was $9.0 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal third quarter ended March 31, 2025. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Total revenues were $60

      5/21/25 7:01:00 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions to Host Fiscal Third Quarter 2025 Financial Results Conference Call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time

      Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Wednesday, May 21, 2025 at 8:30 a.m. Eastern Time to discuss its results for the fiscal third quarter ended March 31, 2025. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube, Chief Commercial Officer Milen Marinov and Head of Investor Relations Paula Savanti will host the conference ca

      5/9/25 4:30:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Bioceres Crop Solutions Reports Fiscal Second Quarter 2025 Financial and Operational Results

      Total revenues in 2Q25 were $106.7 million 2Q25 net income was $0.6 million and Adjusted EBITDA1 was $15.4 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal second quarter ended December 31, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Revenues in

      2/11/25 6:18:00 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bioceres Crop Solutions Corp.

      SC 13G - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      10/23/24 2:32:38 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Bioceres Crop Solutions Corp.

      SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      9/20/24 9:09:41 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Bioceres Crop Solutions Corp. (Amendment)

      SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      3/25/24 8:58:35 AM ET
      $BIOX
      Agricultural Chemicals
      Industrials

    $BIOX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Bioceres Crop Solutions Corp.

      SCHEDULE 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)

      6/10/25 5:57:54 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Bioceres Crop Solutions Corp.

      6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)

      5/21/25 4:44:06 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials
    • SEC Form 6-K filed by Bioceres Crop Solutions Corp.

      6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)

      3/11/25 4:01:14 PM ET
      $BIOX
      Agricultural Chemicals
      Industrials